Treatment with the LSD1i did not reduce numbers of LT-HSCs in CR-fed mice, nor it did it in most other BM subpopulations, including multilineage progenitors (MPPs; Lineage−, Sca+, c-Kit+, CD34+, Flk+), myeloblasts (which were increased), myeloid derived suppressor cells (no change), myelocytes (no change), with the exception of erythroid-committed cells, which are well-known specific targets of LSD1i44, causing a reversible anemia (Supplementary Fig. 4f), thus suggesting that the LSD1-dependency is a specific vulnerability of leukemic cells. This evidence concerns the gene CD34 and anemia (phenotype).